Filgrastim
- Generic Name
- Filgrastim
- Brand Names
- Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 121181-53-1
- Unique Ingredient Identifier
- PVI5M0M1GW
- Background
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...
- Indication
Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...
- Associated Conditions
- Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
- Associated Therapies
- Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy
GCSF Therapy in Decompensated Cirrhosis - A Double Blinded RCT
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2019-07-19
- Target Recruit Count
- 70
- Registration Number
- NCT03911037
- Locations
- 🇮🇳
Post Graduate Institute of Medical Education and Research, Chandigarh, India
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
- Conditions
- Lymphocyte-Rich Classic Hodgkin LymphomaAnn Arbor Stage III Hodgkin LymphomaClassic Hodgkin LymphomaAnn Arbor Stage III Nodular Sclerosis Classic Hodgkin LymphomaAnn Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin LymphomaAnn Arbor Stage IV Mixed Cellularity Classic Hodgkin LymphomaAnn Arbor Stage IV Nodular Sclerosis Classic Hodgkin LymphomaAnn Arbor Stage III Lymphocyte-Depleted Classic Hodgkin LymphomaAnn Arbor Stage III Mixed Cellularity Classic Hodgkin LymphomaAnn Arbor Stage IV Hodgkin Lymphoma
- Interventions
- Procedure: Biospecimen CollectionDrug: Brentuximab VedotinProcedure: Computed TomographyDrug: DacarbazineDrug: Doxorubicin HydrochlorideBiological: FilgrastimProcedure: Magnetic Resonance ImagingBiological: NivolumabBiological: PegfilgrastimProcedure: Positron Emission TomographyOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Radiation TherapyDrug: Vinblastine Sulfate
- First Posted Date
- 2019-04-09
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 995
- Registration Number
- NCT03907488
- Locations
- 🇺🇸
Corewell Health Beaumont Troy Hospital, Troy, Michigan, United States
🇺🇸Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States
🇺🇸Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti, Michigan, United States
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2019-02-27
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT03856216
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Autologous Transplant To End NMO Spectrum Disorder
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT03829566
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States
Intrauterine G-CSF Administration in RIF
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Gurgan Clinic
- Target Recruit Count
- 157
- Registration Number
- NCT03783208
- Locations
- 🇹🇷
Gurgan Clinic IVF and Women Health Center, Ankara, Cankaya, Turkey
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
- Conditions
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT03755804
- Locations
- 🇺🇸
Maine Children's Cancer Program, Scarborough, Maine, United States
🇺🇸St. Jude Affiliate Baton Rouge Clinic (Our Lady of the Lakes Regional Medical Center), Baton Rouge, Louisiana, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML
- Conditions
- Interventions
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2020-05-20
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 16
- Registration Number
- NCT03661515
- Locations
- 🇪🇸
Hospital San Pedro de Alcántara,, Cáceres, Spain
🇪🇸Hospital la Fe, Valencia, Spain
🇪🇸Hospital Germans Tries i Pujol, Badalona, Badalona, Spain
131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Registration Number
- NCT03649438
- Locations
- 🇺🇸
The University of Texas Southwestern Medical Center, Dallas, Texas, United States
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 255
- Registration Number
- NCT03646123
- Locations
- 🇺🇸
Texas Oncology - Flower Mound, Flower Mound, Texas, United States
🇺🇸Clinical Research Alliance - Abraham Mittelman, MD, LLC, Purchase, New York, United States
🇨🇿Fakultni Nemocnice Kralovske Vinohrady, Praha 10, Other, Czechia
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT03600909
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.